Pfizer's Lyrica misses endpoints in peripheral neuropathic pain study

US pharma giant Pfizer’s (NYSE: PFE) shares were up 3.08% to $32.95 by around midday Wednesday, despite the company releasing disappointing results for its blockbuster pain drug Lyrica (pregabalin).

Pfizer announced top-line results of a Phase III trial evaluating the efficacy and safety of Lyrica capsules CV in adults with chronic post-traumatic peripheral neuropathic pain, showing that the study did not meet its primary efficacy endpoint.

The trial was conducted as a 15-week, double-blind, placebo-controlled, parallel group study with a primary objective to evaluate the efficacy of pregabalin in the treatment of chronic post-traumatic peripheral neuropathic pain. The primary efficacy endpoint was mean pain reduction from baseline compared with placebo based on pain scores from patients’ daily pain diaries. The safety profile observed in this study was consistent with that known for pregabalin. The most common adverse events with pregabalin in this study were dizziness, somnolence, nausea and fatigue.